Trial of Tykerb for HER2-Positive Breast Cancer Brain Mets Begins

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 1
Volume 15
Issue 1

SAN ANTONIO—GlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.

SAN ANTONIO—GlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.

Articles in this issue
FDA Approves Nexavar for Use in Advanced Kidney Cancer
Avastin Benefits Metastatic Breast Cancer
Amgen to Acquire Abgenix
Better Prognosis for ‘Elsewhere' Local Breast Ca Recurrences
Herceptin/Taxotere Ups DFS in Early HER2+ Breast Ca
NIH 2006 Budget Is Likely to Be Lower Than in 2005
Amooranin, a Plant Compound, Shows Potential as Cancer Treatment
Mesenchymal Stem Cell Transplantation Potential Novel Treatment for Patients With Severe Graft-vs-Host-Disease
FDA Launches 7 Initiatives With European Drug Regulators
Taxanes Comparable as Adjuvant Therapy of Breast Cancer; Weekly Paclitaxel More Effective Than q3wk
Lessons From Ongoing Clinical Experience With MammoSite Breast Brachytherapy
Antibody Detects AML-Associated Stem Cells
Trial of Tykerb for HER2-Positive Breast Cancer Brain Mets Begins
Len/Dex for Relapsed or Refractory Myeloma
Encouraging Results With Ixabepilone in Metastatic Breast Ca
Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Related Content
ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBC

ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBC

Spencer Feldman
December 20th 2024
Article

The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.

Top 10 Findings Shaping the Future of Breast Cancer Care From SABCS 2024

Russ Conroy
December 18th 2024
Article

SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

ctDNA at Baseline Linked With Larger Tumor Size and Residual Cancer Burden

ctDNA at Baseline Linked With Larger Tumor Size and Residual Cancer Burden

Ashley Chan
December 14th 2024
Article

Ultra-sensitive ctDNA testing identified ctDNA at baseline in patients with HR–positive breast cancer, results from the PELOPS trial showed.

Health-Related Quality of Life Complimented Efficacy/Safety With T-DXd in Breast Cancer

Health-Related Quality of Life Complimented Efficacy/Safety With T-DXd in Breast Cancer

Kyle Doherty
December 13th 2024
Article